Synonyms: GS-6207 | GS6207 | Sunlenca®
lenacapavir is an approved drug (EMA & FDA (2022))
Compound class:
Synthetic organic
Comment: Lenacapavir (GS-6207) is a novel long-acting anti-HIV lead that binds to the virus' at a conserved interface between capsid protein monomers [2]. This mechanism disrupts early and late phases of the viral replication cycle [1] [3]. PDB entry 6V2F shows the crystal structure of lenacapavir-bound HIV capsid hexamer.
|
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04143594 | Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV | Phase 2 Interventional | Gilead Sciences | ||
NCT04150068 | Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance | Phase 2/Phase 3 Interventional | Gilead Sciences | ||
NCT03739866 | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults | Phase 1 Interventional | Gilead Sciences | 2 |
External links ![]() |
For extended ADME data see the following: European Medicines Agency (EMA) |